Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform
- Written by PR Newswire
![]() |
CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. Under the agreement, Ailux Biologics...














